BCL2 and BCLxL are key determinants of resistance to antitubulin chemotherapeutics in melanoma cells

Experimental Dermatology

Volumn 22, Issue 8, 2013, Pages 518-523

  Watanabe, Ayano ^a   Yasuhira, Shinji ^a   Inoue, Tsuyoshi ^a   Kasai, Shuya ^a   Shibazaki, Masahiko ^a   Takahashi, Kazuhiro ^a   Akasaka, Toshihide ^a   Masuda, Tomoyuki ^a   Maesawa, Chihaya ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Apoptosis; BCL2; BCLxL; Melanoma; Paclitaxel

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; PACLITAXEL; PROTEIN BCL 2; PROTEIN BCL XL;

APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MELANOMA CELL; MITOSIS INHIBITION;

EID: 84880752633     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/exd.12185     Document Type: Article

References (36)

1. Davies H, Bignell G R, Cox C et al. Nature 2002: 417: 949-954.
2. Puig-Butille J A, Badenas C, Ogbah Z et al. Exp Dermatol 2013: 22: 148-150.
3. Wong S, Witte O N. Annu Rev Immunol 2004: 22: 247-306.
4. Bollag G, Tsai J, Zhang J et al. Nat Rev Drug Discov 2012: 11: 873-886.
5. Legha S S, Ring S, Papadopoulos N et al. Cancer 1990: 65: 2478-2481.
6. Walker L, Schalch H, King D M et al. Melanoma Res 2005: 15: 453-459.
7. Bhalla K N. Oncogene 2003: 22: 9075-9086.
8. Nogales E, Wolf S G, Khan I A et al. Nature 1995: 375: 424-427.
9. Blagosklonny M V. Cell Cycle 2007: 6: 70-74.
10. Puthalakath H, Huang D C, O'Reilly L A et al. Mol Cell 1999: 3: 287-296.
11. Rieder C L, Maiato H. Dev Cell 2004: 7: 637-651.
12. Hari M, Loganzo F, Annable T et al. Mol Cancer Ther 2006: 5: 270-278.
13. Mozzetti S, Ferlini C, Concolino P et al. Clin Cancer Res 2005: 11: 298-305.
14. Kaira K, Takahashi T, Murakami H et al. Int J Clin Oncol 2012. doi:10.1007/s10147-012-0386-8 .
15. Kavallaris M. Nat Rev Cancer 2010: 10: 194-204.
16. Akasaka K, Maesawa C, Shibazaki M et al. J Invest Dermatol 2009: 129: 1516-1526.
17. Youle R J, Strasser A. Nat Rev Mol Cell Biol 2008: 9: 47-59.
18. Wertz I E, Kusam S, Lam C et al. Nature 2011: 471: 110-114.
19. Inuzuka H, Shaik S, Onoyama I et al. Nature 2011: 471: 104-109.
20. Plettenberg A, Ballaun C, Pammer J et al. Am J Pathol 1995: 146: 651-659.
21. von Willebrand M, Kohler K, Alanko T et al. Exp Dermatol 2005: 14: 202-208.
22. Zhai S, Yaar M, Doyle S M et al. Exp Cell Res 1996: 224: 335-343.
23. Borner C. Melanoma Res 1999: 9: 347-350.
24. McGill G G, Horstmann M, Widlund H R et al. Cell 2002: 109: 707-718.
25. Ilmonen S, Hernberg M, Pyrhonen S et al. Melanoma Res 2005: 15: 375-381.
26. Leiter U, Schmid R M, Kaskel P et al. Arch Dermatol Res 2000: 292: 225-232.
27. Selzer E, Schlagbauer-Wadl H, Okamoto I et al. Melanoma Res 1998: 8: 197-203.
28. Tron V A, Krajewski S, Klein-Parker H et al. Am J Pathol 1995: 146: 643-650.
29. Skvara H, Thallinger C, Wacheck V et al. Anticancer Res 2005: 25: 2697-2703.
30. Oltersdorf T, Elmore S W, Shoemaker A R et al. Nature 2005: 435: 677-681.
31. Oda S, Nishida J, Nakabeppu Y et al. Oncogene 1995: 10: 1343-1351.
32. Jackisch C, Hahm H A, Tombal B et al. Clin Cancer Res 2000: 6: 2844-2850.
33. Yin S, Cabral F, Veeraraghavan S. Mol Cancer Ther 2007: 6: 2798-2806.
34. Raisova M, Hossini A M, Eberle J et al. J Invest Dermatol 2001: 117: 333-340.
35. Basu A, Haldar S. FEBS Lett 2003: 538: 41-47.
36. Shajahan A N, Dobbin Z C, Hickman F E et al. J Biol Chem 2012: 287: 17682-17692.